ABSI
Absci Corporation
$7.13
-0.43
(-5.69%)
Mkt Cap
1.21B
Volume
2,849,679
52W Range
2.24-12.055
Sector
Healthcare
Beta
2.33
EPS (TTM)
-0.83
P/E Ratio
-4.15
Revenue (TTM)
1.84M
Rev Growth (5Y)
-10.1%
EPS Growth (5Y)
N/A
Company Description
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Net Income | (115.18M) | (103.11M) | (110.57M) | (104.90M) | (100.96M) | (14.35M) | (6.58M) |
| EPS | -0.84 | -0.94 | -1.20 | -1.15 | -1.11 | -0.54 | -0.07 |
| Free Cash Flow | (94.03M) | (72.81M) | (65.50M) | (97.51M) | (98.64M) | (13.15M) | (7.13M) |
| FCF / Share | -0.69 | -0.66 | -0.71 | -1.07 | -1.06 | -0.14 | -0.08 |
| Operating CF | (92.92M) | (72.40M) | (64.64M) | (81.34M) | (60.60M) | (10.97M) | (6.03M) |
| Total Assets | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M | 88.57M | 19.47M |
| Total Debt | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M | 14.50M | 6.02M |
| Cash & Equiv | 20.02M | 41.21M | 72.36M | 59.95M | 252.57M | 69.87M | 13.09M |
| Book Value | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M | 67.00M | (41.16M) |
| Return on Equity | -0.61 | -0.58 | -0.63 | -0.38 | -0.28 | -0.21 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215,000 | 650,000 | 378,000 | 593,000 | 1.18M | 665,000 | 1.70M | 1.27M | 898,000 | 338,000 | 744,000 | 3.37M |
| Net Income | (29.60M) | (29.56M) | (28.71M) | (30.57M) | (26.35M) | (28.98M) | (27.40M) | (24.75M) | (21.98M) | (23.55M) | (21.99M) | (41.67M) |
| EPS | -0.19 | -0.20 | -0.20 | -0.24 | -0.21 | -0.25 | -0.24 | -0.22 | -0.22 | -0.25 | -0.24 | -0.45 |
| Free Cash Flow | (26.34M) | (29.08M) | (25.99M) | (17.10M) | (21.86M) | (16.99M) | (20.78M) | (17.18M) | (17.86M) | (14.94M) | (10.67M) | (19.49M) |
| FCF / Share | -0.17 | -0.19 | -0.18 | -0.13 | -0.18 | -0.15 | -0.18 | -0.15 | -0.18 | -0.16 | -0.12 | -0.21 |
| Operating CF | (26.31M) | (29.18M) | (25.03M) | (16.87M) | (21.84M) | (16.96M) | (20.73M) | (16.84M) | (17.86M) | (14.92M) | (10.36M) | (19.23M) |
| Total Assets | 195.59M | 216.30M | 244.99M | 209.89M | 232.45M | 213.61M | 235.23M | 255.53M | 274.90M | 217.30M | 236.34M | 254.15M |
| Total Debt | 4.42M | 5.30M | 6.22M | 7.41M | 8.92M | 10.11M | 11.99M | 13.33M | 14.24M | 15.88M | 17.75M | 19.47M |
| Cash & Equiv | 8.63M | 20.02M | 9.48M | 38.02M | 46.99M | 41.21M | 38.20M | 42.94M | 58.83M | 72.36M | 69.73M | 61.05M |
| Book Value | 171.97M | 189.45M | 210.34M | 173.37M | 198.80M | 179.13M | 201.34M | 221.49M | 240.11M | 176.18M | 196.42M | 215.40M |
| Return on Equity | -0.17 | -0.16 | -0.14 | -0.18 | -0.13 | -0.16 | -0.14 | -0.11 | -0.09 | -0.13 | -0.11 | -0.19 |
ABSI News
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery